GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
31
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Vaccines & Global Health
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
89
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Conrad
b)
Position/status
SVP, Human Resources
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
6
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr J Ford
b)
Position/status
SVP & General Counsel
c)
Initial notification/amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
4
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms S Jackson
b)
Position/status
SVP, Global Communications and CEO Office
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
82
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Jackson
b)
Position/status
PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
32
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Miels
b)
Position/status
Chief Commercial Officer
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
5
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
100
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Simard
b)
Position/status
President, Pharmaceuticals Supply Chain
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
31
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
60
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms D Waterhouse
b)
Position/status
Chief Executive Officer of ViiV Healthcare
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
80
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms V Whyte
b)
Position/status
Company Secretary
c)
Initial notification/amendment

Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 October 2021, on shares held through the Company's Share Reward Plan.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£13.9389
74
d)
Aggregated information
N/A (single transaction)
Aggregated volume
Price
e)
Date of the transaction
2021-10-07
f)
Place of the transaction
London Stock Exchange (XLON)

Attachments

  • Original document
  • Permalink

Disclaimer

GSK - GlaxoSmithKline plc published this content on 12 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2021 15:11:04 UTC.